Document is current
Any future updates will be listed below
-
Authors
Ponce-Ibarra, Alfonso https://orcid.org/0000-0001-9953-4480
Hennies, Nora
Newson, Rachel S. https://orcid.org/0000-0002-2653-5797
Artime, Esther https://orcid.org/0000-0003-4294-6462
Spaepen, Erik https://orcid.org/0000-0001-7590-7844
Kempe, Hans-Peter
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 30 May 2025
First Online: 23 June 2025
Declarations
:
: These data were previously presented in part at Deutsche Diabetes Gesellschaft – Diabetes Kongress: Patient and Healthcare Professional Experiences of Suboptimal Insulin Dosing in Germany. (DDG, 17–20 May 2023). Alfonso Ponce-Ibarra, Nora Hennies, Rachel Newson, and Esther Artime are employees and minor stake/shareholders of Eli Lilly and Company. Erik Spaepen is a contractor at Eli Lilly and Company via HaaPACS, Schriesheim, Germany. Hans-Peter Kempe is an advisor or speaker for and/or has received research grants/payments from Eli Lilly and Company.
: A centralised Ethical & Independent (E&I) review service reviewed the conduct of the multi-country study (E&I Study Number 21052-01A, approved on 16 Nov 2021). Informed consent was obtained by the researchers from all individual participants included in the study.
